As at November 15, 2024Show prices
SaskWorks Diversified (Class A - Series A) - 27.5059
SaskWorks Diversified (Class A - Series B) - 29.8056
SaskWorks Diversified (Class A - Series F) - 33.0756
SaskWorks Resources (Class R - Series A) - 26.9724
SaskWorks Resources (Class R - Series B) - 35.3832
SaskWorks Resources (Class R - Series F) - 30.0659
Tamarack Valley Energy Ltd. (“Tamarack” or the “Company”) (TVE.TO) is pleased to announce the results of its independent oil and gas reserves evaluation as of December 31, 2016, prepared by GLJ Petroleum Consultants Ltd. (“GLJ”), summarized below. The reserves evaluation contained herein does not include the impact of the Spur Resources Ltd. acquisition,,,
When Jared and Abby Wolfe first told their friends and family they were moving everyone was confused. Why would two young university students want to live in a place with a bunch of seniors?
Crescent Point Energy Corp. (“Crescent Point” or the “Company”) (CPG) (CPG) is pleased to announce its operating and financial results for the year ended December 31, 2016. The Company also announces that its audited financial statements and management’s discussion and analysis for the year ended December 31, 2016…
TORONTO, ONTARIO–(Marketwired – Feb 21, 2017) – STORAGEVAULT CANADA INC. (“StorageVault”) (TSX VENTURE:SVI) announced today that it understands that Access Self Storage Inc. (“Access”) has acquired 15,000,000 common shares in the capital of StorageVault (“Common Shares”) at a price of $1.50 per share, representing an aggregate purchase price of $22,500,000…
Today, CanniMed Therapeutics Inc. (TSX: CMED) and CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) have entered into a definitive contractual relationship for the licensing of CTT’s Orally Dissolvable Thin Film (ODF) Wafer technology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170217005365/en/
This industry-first collaboration includes the licensing of six patents related to cannabinoid and opioid delivery for pain management, which will enable CMED to exclusively develop and commercialize this novel, smoke-free, drug delivery system in Canada.
As one of the major symptoms experienced by patients with Multiple Sclerosis (MS), neuropathic pain can be extremely debilitating. A leading neuro-immunology team lead by Dr. Michael Namaka at the University of Manitoba in Winnipeg, Manitoba, is looking to determine the analgesic efficacy of two of CanniMed Therapeutics Inc. (TSX: CMED) cannabinoid plant derived oil extracts using a rodent model of MS-induced neuropathic pain.
CanniMed Therapeutics Inc. (CMED.TO) (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, provides the following updates to shareholders related to patient growth rates, sales volumes and product supply.
Please select the option that best describes you: